HTGF, Think.Health Ventures and Business Angels have also supplied funding to Max Planck Institute for Biochemistry mass spectrometry spinout PreOmics.

PreOmics, a Germany-based mass spectrometry sampling technology business based on research from Max Planck Institute for Biochemistry, has obtained €3.3m ($3.8m) in a series A round backed by public-private partnership High-Tech Gründerfonds.
The round was led by Think.Health Ventures with participation from syndicate Business Angels.
Founded in 2016, PreOmics has devised a technology that helps prepare standardised samples for mass spectrometry research so that project teams can improve the chances of achieving robust and reproducible results.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?